3.2404
3.51%
0.1104
前日終値:
$3.13
開ける:
$3.17
24時間の取引高:
373.12K
Relative Volume:
0.30
時価総額:
$526.01M
収益:
-
当期純損益:
$-54.70M
株価収益率:
-11.57
EPS:
-0.28
ネットキャッシュフロー:
$-51.36M
1週間 パフォーマンス:
+1.57%
1か月 パフォーマンス:
-9.24%
6か月 パフォーマンス:
-24.65%
1年 パフォーマンス:
-13.14%
Savara Inc Stock (SVRA) Company Profile
SVRA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
SVRA | 3.24 | 526.01M | 0 | -54.70M | -51.36M | -0.28 |
VRTX | 448.33 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 590.33 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.50 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-11-07 | 開始されました | Guggenheim | Buy |
2023-05-16 | アップグレード | Jefferies | Hold → Buy |
2023-03-31 | ダウングレード | Jefferies | Buy → Hold |
2021-03-16 | 開始されました | Piper Sandler | Overweight |
2021-03-15 | 開始されました | Oppenheimer | Outperform |
2019-06-13 | 繰り返されました | H.C. Wainwright | Buy |
2019-06-13 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2019-06-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
2018-08-13 | 再開されました | ROTH Capital | Neutral |
2018-01-03 | 開始されました | Ladenburg Thalmann | Buy |
2017-09-27 | 再開されました | ROTH Capital | Buy |
2017-09-22 | 開始されました | Jefferies | Buy |
2017-09-11 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Savara Inc (SVRA) 最新ニュース
Independent Director of Savara Picks Up 4.5% More Stock - Simply Wall St
Savara Inc. Reports Third-Quarter Financial Results and Announces Key Regulatory Milestones - MSN
Insider Buying Alert: Joseph Mccracken Acquires 20,000 Shares of Savara Inc (SVRA) - GuruFocus.com
Savara director Joseph McCracken acquires $59,071 in common stock - Investing.com India
Director David Ramsay Acquires 100,000 Shares of Savara Inc (SVR - GuruFocus.com
Savara Inc director David Ramsay buys $287,600 in common stock - Investing.com
Savara Inc director David Ramsay buys $287,600 in common stock By Investing.com - Investing.com UK
Savara (NASDAQ:SVRA) Shares Down 8.5%Time to Sell? - MarketBeat
Prudential Financial Inc's Strategic Acquisition of Savara Inc S - GuruFocus.com
What is HC Wainwright's Estimate for Savara FY2024 Earnings? - MarketBeat
Evercore ISI Reiterates In-Line Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
SVRA stock touches 52-week low at $3.27 amid market challenges - Investing.com India
500: Something went wrong - Investing.com Canada
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate - GuruFocus.com
Savara downgraded at Evercore on manufacturing concerns for lung disease candidate - Seeking Alpha
Savara (NASDAQ:SVRA) Shares Gap Down on Analyst Downgrade - MarketBeat
Savara (NASDAQ:SVRA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Savara (NASDAQ:SVRA) Earns "In-Line" Rating from Evercore ISI - MarketBeat
Savara (SVRA) to Present at Jefferies and Piper Sandler Healthcare Conferences | SVRA Stock News - StockTitan
Jennison Associates LLC's Strategic Acquisition of Savara Inc Sh - GuruFocus.com
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Savara Inc (NASDAQ:SVRA) Receives $11.17 Average Price Target from Analysts - MarketBeat
Savara Inc. to Participate in Guggenheim Inaugural Healthcare Conference - MyChesCo
Savara Fast-Tracks MOLBREEVI FDA Filing Despite Widening Q3 Losses, $219M Cash Runway | SVRA Stock News - StockTitan
Wellington Management Group LLP's Strategic Acquisition in Savar - GuruFocus.com
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara (NASDAQ:SVRA) Stock Price Down 5.1%Should You Sell? - MarketBeat
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference - StockTitan
Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature - MSN
Savara Inc. Rewards New Employees with Inducement Awards - MSN
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV - Business Wire
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV - Yahoo Canada Finance
Savara Announces New Employment Inducement Grant - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Savara Announces New Employment Inducement Grant | SVRA Stock News - StockTitan
Savara Inc (SVRA) deserves deeper analysis - US Post News
Ratio Review: Analyzing Savara Inc (SVRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Savara Inc (SVRA) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara maintains Overweight rating from Piper Sandler on bullish aPAP therapy prospects - Investing.com UK
Savara (NASDAQ:SVRA) Trading Down 3.4%Here's What Happened - MarketBeat
Cantaloupe, Inc. Executives Boost Confidence with Significant Stock Purchases - MyChesCo
Savara stock outlook steady as H.C. Wainwright highlights challenges in doctor engagement at CHEST meeting - Investing.com
Savara (NASDAQ:SVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Should investors be concerned about Savara Inc (SVRA)? - US Post News
The growth track for Savara Inc (SVRA) has changed recently - SETE News
Stock Surge: Savara Inc (SVRA) Closes at 3.82, Marking a 0.26 Increase/Decrease - The Dwinnex
Marshall Wace LLP Has $1.23 Million Stake in Savara Inc (NASDAQ:SVRA) - MarketBeat
Algert Global LLC Boosts Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. Grants Inducement Awards to New Employee - MSN
Savara Inc (SVRA) 財務データ
収益
当期純利益
現金流量
EPS
Savara Inc (SVRA) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
RAMSAY DAVID A | Director |
Nov 18 '24 |
Buy |
2.88 |
100,000 |
287,600 |
2,323,642 |
Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 28 '23 |
Sale |
4.71 |
84,000 |
395,900 |
1,302,674 |
Lowrance David L | CHIEF FINANCIAL OFFICER |
Dec 28 '23 |
Sale |
4.71 |
10,000 |
47,131 |
342,355 |
Elam Nevan C | Director |
Dec 28 '23 |
Option Exercise |
1.30 |
53,758 |
69,722 |
116,343 |
Elam Nevan C | Director |
Dec 28 '23 |
Sale |
4.71 |
93,843 |
442,291 |
22,500 |
Hawkins Richard J | Director |
Dec 11 '23 |
Option Exercise |
0.82 |
10,841 |
8,890 |
12,741 |
Elam Nevan C | Director |
Dec 11 '23 |
Option Exercise |
0.82 |
10,841 |
8,890 |
40,085 |
大文字化:
|
ボリューム (24 時間):